UNICANCER
🇧🇷Brazil
- Country
- 🇧🇷Brazil
- Ownership
- Private
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.unicancer.fr
Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: HAIC (GEMOX)
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 196
- Registration Number
- NCT06904170
- Locations
- 🇫🇷
CHU de Bordeaux, Bordeaux, France
🇫🇷AP-HP Hôpital Beaujon, Clichy, France
🇫🇷Centre Georges Francois Leclerc, Dijon, France
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Metastatic Esophageal AdenocarcinomaAdvanced Esophageal AdenocarcinomaMetastatic Gastric AdenocarcinomaAdvanced Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 88
- Registration Number
- NCT06846346
- Locations
- 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷Institut de Cancerologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
Phase 2
Not yet recruiting
- Conditions
- Breast Cancer MetastaticBreast Cancer Stage IV
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 80
- Registration Number
- NCT06680596
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 40
- Registration Number
- NCT06653777
- Locations
- 🇫🇷
CHU de BREST, Brest, France
🇫🇷Centre Antoine Lacassagne, Nice, France
🇫🇷Institut Curie, Paris, France
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Phase 3
Recruiting
- Conditions
- High Risk Prostate CarcinomaProstate Cancer
- Interventions
- Drug: ADT (Standard of Care)Radiation: Stereotactic Body RadioTherapy (SBRT)Radiation: radiotherapy
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 700
- Registration Number
- NCT06625970
- Locations
- 🇫🇷
Clinique Pasteur Lanroze - Brest, Brest, France
🇫🇷Centre Georges Francois Leclerc, Dijon, France
🇫🇷Groupe Hospitalier Paris Saint-Joseph, Paris, France
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
Phase 3
Not yet recruiting
- Conditions
- Breast CancersTriple Negative Breast Cancer (TNBC)
- Interventions
- Other: Deescalation
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 2454
- Registration Number
- NCT06606730
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Phase 2
Not yet recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- Drug: FOLFOX regimen
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 72
- Registration Number
- NCT06529718
- Locations
- 🇧🇪
Cliniques universitaires Saint-Luc, Brussels, Belgium
🇫🇷Institute Mutualiste Montsouris, Paris, France
🇫🇷Centre Eugène Marquis, Rennes, France
Blood Biomarkers Based Screening for HPV-driven OPC
Not Applicable
Not yet recruiting
- Conditions
- Head and Neck Squamous Cell CarcinomaHuman Papilloma VirusAnal Cancer
- Interventions
- Diagnostic Test: HPV16-E6 serology and HPV ctDNA
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 10000
- Registration Number
- NCT06528353
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 198
- Registration Number
- NCT06524583
- Locations
- 🇫🇷
Institut de Cancerologie de L'Ouest (Ico), Angers, France
🇫🇷Hopital Jean Minjoz, Besancon, France
🇫🇷Institut Bergonie, Bordeaux, France
Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
Not Applicable
Recruiting
- Conditions
- Metastatic Triple-Negative Breast Carcinoma
- Interventions
- Device: Cureety techcare
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 472
- Registration Number
- NCT06505018
- Locations
- 🇫🇷
Institut de Cancérologie des Hauts-de-France (ICHF), Arras, France
🇫🇷Centre Hospitalier d'Auxerre, Auxerre, France
🇫🇷Sainte Catherine - Institut du Cancer Avignon Provence, Avignon, France